Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Elevance Health Inc. Revenue & Financial Statements
Elevance Health Inc. reported revenue of $199.1B for the fiscal year ended December 31, 2025, up 12.5% year over year, with net income of $5.7B and diluted EPS of $25.21.
- Company
- Elevance Health Inc. ELV · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 138.6B | 156.6B | 171.3B | 177.0B | 199.1B |
| Cost of revenue | 10.9B | 13.0B | 17.3B | 19.8B | 21.2B |
| Gross profit | 127.7B | 143.6B | 154.0B | 157.3B | 177.9B |
| Operating income | 7.5B | 8.5B | 8.5B | 7.9B | 7.2B |
| Pretax income | 7.9B | 7.8B | 7.7B | 7.9B | 388.0M |
| Net income | 5.8B | 3.7B | 7.2B | 6.1B | 5.7B |
| Diluted EPS | 24.73 | 24.81 | 25.22 | 25.68 | 25.21 |
| EBITDA | 7.6B | 8.6B | 8.6B | 8.0B | 7.3B |
Quarterly
| USD | Q4 '24 | Q2 '25 | Q1 '25 | Q3 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45.4B | — | 48.9B | — | 49.8B | 50.7B | 49.7B | 50.2B |
| Cost of revenue | 6.0B | — | 5.0B | — | 5.3B | 5.4B | 5.5B | 5.5B |
| Gross profit | 39.4B | — | 43.9B | — | 44.5B | 45.3B | 44.2B | 44.7B |
| Operating income | 673.0M | — | 3.2B | — | 2.4B | 1.3B | 309.0M | 2.1B |
| Pretax income | 606.0M | — | 2.8B | — | 2.3B | 1.4B | 215.0M | 2.3B |
| Net income | (240.0M) | 2.2B | 2.4B | 1.7B | 1.9B | 1.4B | 546.0M | 1.8B |
| Diluted EPS | 1.87 | — | 9.61 | — | 7.72 | 5.32 | 2.54 | 8.00 |
| EBITDA | — | — | — | — | — | — | — | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 97.5B | 102.8B | 108.9B | 116.9B | 121.5B |
| Current assets | 51.1B | 55.6B | 60.0B | 58.9B | 63.0B |
| Cash & equivalents | 4.9B | 7.4B | 6.5B | 8.3B | 9.5B |
| Total liabilities | 61.3B | 66.4B | 69.5B | 75.5B | 77.5B |
| Current liabilities | 34.9B | 39.7B | 41.8B | 40.6B | 41.0B |
| Long-term debt | 21.2B | 22.3B | 23.2B | 29.2B | 30.8B |
| Total debt | 21.4B | 22.6B | 23.5B | 29.6B | 30.9B |
| Stockholders’ equity | 36.1B | 36.3B | 39.3B | 41.3B | 43.9B |
| Net debt | 16.6B | 15.2B | 16.9B | 21.3B | 21.5B |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 8.4B | 8.4B | 8.1B | 5.8B | 4.3B |
| Investing cash flow | (9.6B) | (4.6B) | (5.6B) | (5.2B) | (1.3B) |
| Financing cash flow | 423.0M | (1.3B) | (3.3B) | 1.2B | (1.7B) |
| Capital expenditure | 1.1B | 1.2B | 1.3B | 1.3B | 1.1B |
| Free cash flow | 7.3B | 7.2B | 6.8B | 4.6B | 3.2B |
| Dividends paid | 1.1B | 1.2B | 1.4B | 1.5B | 1.5B |
| Stock-based compensation | 255.0M | 264.0M | 289.0M | 191.0M | 276.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every ELV filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.